SBIR/STTR Research Award

Microbial symbionts of marine invertebrates for antibiotic discovery

Award identifier e6df3591b5ec52f9a5e825a6daa6ae91277feec02c2b96b1c2f49007ab5e0b3eAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$224,356

Program and phase

SBIR · Phase I

Award year

2015

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
NOVOBIOTIC PHARMACEUTICALS, LLC
Proposal award date
2015-07-01
Contract end date
2015-12-31
UEI
GUV4CZLZE5Z2
Solicitation number
PA14-071
Topic code
NIAID

Research abstract

DESCRIPTION provided by applicant The overall goal of this project is to discover novel antibiotics to combat important drug resistant pathogens One effective countermeasure against such pathogens is novel antibiotics but the rate of antibiotic discovery has been in steady decline All the more recently introduced antibiotics are derivatives of older antibiotics or resulted from revival of initially discarded compounds which were discovered decades ago such as daptomycin linezolid synercid and fidaxomycin Clinically used antibiotics have traditionally been discovered by screening for active secondary metabolites of readily culturable microorganisms This resource represents andlt of all microbial diversity in nature The other andgt unexplored and previously unavailable microorganisms are arguably the single most promising resource for novel antibiotics NovoBiotic directly addresses the bottleneck of antibiotic discovery by using unique cultivation approaches the diffusion chamber and trap methodologies to isolate previously andquot uncultivableandquot microorganisms This approach has resulted in new compounds so far at a rate far higher than the predicted industry standard Several of these compounds are of principal novelty and are in development including Novo a DNA G quadruplex binder currently in development as an anti cancer agent in collaboration with the National Cancer Institute Novo a macrolactam inhibitor of cell wall biosynthesis lassomycin an inhibitor of the essential ClpP P C protease of M tuberculosis and teixobactin a novel cell wall synthesis inhibitor This project takes the next step and extends the technology to shallow water marine invertebrate microbe symbioses ubiquitously present and easily accessible in local communities From the limited exploration conducted to date a number of bioactive compounds with unique properties have been discovered from marine symbioses including anti tumor and anti microbial compounds There is strong evidence that it is the associated microorganisms living in association with the host invertebrates that produce the bioactive compounds We will develop our methods to isolate novel microbial species living in association with marine invertebrates and screen these strains for antimicrobial activity We will compare the diversity and novelty of active compounds from strains isolated from the diffusion chamber trap and conventional plating The end result of this Phase I project will be proof of concept of new technologies to discover antibiotics from a poorly explored source of microbial diversity formerly andquot uncultivableandquot microbial species from marine invertebrate microbe symbioses PUBLIC HEALTH RELEVANCE It is widely recognized that new antibiotics are needed to combat drug resistant bacterial infections The proposed study will exploit the previously inaccessible microbial diversity of marine invertebrate symbionts to discover novel antibiotics

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

25 SBIR/STTR records share this UEI (2004–2023). Reported award amounts total $36,654,092. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.